Branch Retinal Vein Occlusion

Evaluation and management of branch retinal vein occlusion.

What is a Branch Retinal Vein Occlusion?

A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.

Read more

Lucentis for Branch Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with branch retinal vein occlusion and macular edema. Without treatment about 30 percent of have visual improvement. With treatment about 60 percent of patients have improved vision. Long term follow-up show that at 4 years, about half of the patients with branch retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Branch Retinal Vein Occlusion

Eylea was approved for treatment of branch retinal vein occlusion in late 2014. It is administered as an intravitreal injection monthly initially and then the treatment interval can be extended.


Branch Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Branch Retinal Vein Occlusion

This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Marea Informative

Federated Investors Inc. PA Has $868000 Position in Regeneron Pharmaceuticals Inc (REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov
SEC FORM 4 - SEC.govSEC.gov

all 108 news articles »

Nasdaq

Regeneron Gains on Eylea, Dupixent and Pipeline Progress
Nasdaq
... other countries for the treatment of wet AMD, diabetic macular edema (DME), macular edema following retinal vein occlusion, which includes macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Morse Asset Management Inc Has $2.09 Million Stake in Regeneron Pharmaceuticals Inc (REGN)
Marea Informative (blog)
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Retinal Vein Occlusion Market move up at a CAGR of 11.2% by Topmost Players | By Types Branch Retinal Artery ...
Digital Journal
Complete Study of “Retinal Vein Occlusion Market” Research Report is added on MarketResearchFuture.com with Latest Advancement. Report covered In a Segregated way like Segmentation with sub segments, Growth Barrier, Major Drivers, Renowned ...

and more »

Economic Times

High systolic BP affects your retina and may lead to complete vision loss
Economic Times
In fact, patients who suffer from continuous high systolic blood pressure are 280% more prone to developing severe eye conditions like Central Retinal Vein Occlusion, a condition wherein the central vision is affected leading to loss of sight, than ...


Retinal Vein Occlusion Market Share Analysis 2018 | Registering 11.2% of A CAGR with Renowned Players ...
MENAFN.COM
(MENAFN Editorial) This report provides in-depth qualitative and overall analysis of the' Retinal Vein Occlusion Market' on a regional level from 2018 to 2023. The study also provides a comprehensive review of restraints, Market Dynamics, drivers and ...

and more »

Fairfield Current

Sterling Capital Management LLC Has $566000 Stake in Regeneron Pharmaceuticals Inc (REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Daily Industry Reports

Retinal Vein Occlusion Market Symptoms, Transmission, Diagnosis, Treatment and Prevention 2018
Daily Industry Reports
Global Retinal Vein Occlusion Market Research Report 2018- This report studies the global Retinal Vein Occlusion Market status and forecast, categorizes the global Retinal Vein Occlusion market size (value & volume) by manufacturers, type, application, ...

and more »

Six-month results of intravitreal ranibizumab for macular edema after branch retinal vein occlusion in a single ...
Dove Medical Press
Patients and methods: The inclusion criteria included a minimal patient age of 18 years, 20 letters or more best-corrected visual acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] score, 77 letters or less), and central retinal ...


Fairfield Current

Gabelli Funds LLC Has $862000 Position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov

all 68 news articles »

XNewsPress

Raymond James & Associates Grows Position in Regeneron Pharmaceuticals Inc (REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov

all 56 news articles »

Flagship Harbor Advisors LLC Takes Position in Regeneron Pharmaceuticals Inc (REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.


Placenta Growth Factor Market Research Key Players, Industry Overview, Supply Chain and Analysis to 2018 – 2025
Newszak (blog)
Further, situations of major uses by market portion, development proportion, and sales are included for applications in Branch Retinal Vein Occlusion, Myopia, Neovascular Glaucoma, Others. A strong trend of R&D investments will majorly drive the Global ...


XNewsPress

Regeneron Pharmaceuticals Inc (REGN) Given Average Rating of “Hold” by Analysts
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov
SEC FORM 4 - SEC.govSEC.gov

all 102 news articles »

Express.co.uk

Driving licence WARNING - Inform the DVLA of THIS or risk £1000 fine
Express.co.uk
... Bipolar disorder, Blackouts, Blepharospasm, Blood clots, Blood pressure, Brachial plexus injury, Brain abscess, cyst or encephalitis, Brain aneurysm, Brain angioma, Brain haemorrhage, Brain injury (traumatic), Brain tumours, Branch retinal vein ...


The Casual Smart

Regeneron Pharmaceuticals Inc (REGN) Shares Bought by Great West Life Assurance Co. Can
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Regeneron Pharmaceuticals, Inc. - REGN - Stock Price Today - ZacksZacks
Will Regeneron Close At $400?Seeking Alpha
Regeneron: A Buy On Dupixent And PipelineSeeking Alpha

all 89 news articles »

Spark Investment Management LLC Purchases Shares of 13500 Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Fairfield Current

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Shares Sold by Banque Pictet & Cie SA
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov

all 107 news articles »

PressOracle

Schwab Charles Investment Management Inc. Trims Holdings in Regeneron Pharmaceuticals Inc (REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov

all 31 news articles »

Placenta Growth Factor Market Outlook 2023: Industry Analysis, Top Manufacturer Capacity, Production, Price ...
The FentonPost
Placenta Growth Factor Market provides analysis market status and development trend, types and applications, opportunities for entrant or investor. The Placenta Growth Factor market research report focuses on cost, market growth drivers and challenges, ...


Fairfield Current

Cornerstone Wealth Management LLC Buys Shares of 103937 Regeneron Pharmaceuticals Inc (REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov
SEC FORM 4 - SEC.govSEC.gov

all 51 news articles »

Thorold News

5680 Shares in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Purchased by Altman Advisors Inc.
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov
SEC FORM 4 - SEC.govSEC.gov

all 108 news articles »

Medgadget (blog)

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare at a CAGR of 11.2% by 2023 | By Types Branch ...
Medgadget (blog)
Market Research Future published a research report on “Global Retinal Vein Occlusion Market” to track and analyses developments which are competitive in nature such as strategic alliances, mergers and acquisitions, new product developments along with ...


Barclays Increases Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $305.00
Baseball Daily Digest
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

XNewsPress

Baird Financial Group Inc. Buys 779 Shares of Regeneron Pharmaceuticals Inc (REGN)
XNewsPress
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Sacramento Telescope

Global Placenta Growth Factor Market 2018 – Alteogen Inc., Chengdu Kanghong Pharmaceuticals Group Co Ltd
Sacramento Telescope
Global Placenta Growth Factor market research supported Application: Branch Retinal Vein Occlusion, Myopia, Neovascular Glaucoma, Others. In the following section, the report gives the Placenta Growth Factor company profile, specifications of the ...


IOP spikes more likely after treatment in certain patients
Healio
Patients with uveitis had the greatest mean IOP spike (24.3 mm Hg) compared with patients with central retinal vein occlusion (21.8 mm Hg), branch retinal vein occlusion (21.1 mm Hg) and (20.7 mm Hg) after a single injection. – by Robert Linnehan.


Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in ...
Dove Medical Press
... branch RVO, 70 central RVO) treated with at least three anti-VEGF injections in the study eye was conducted. Available data collected for at least 6 months after the first injection included Snellen best-corrected visual acuity (BCVA), central ...

and more »

Comparison between intravitreal bevacizumab and posterior sub-tenon injection of triamcinolone acetonide in macular ...
Dove Medical Press
Poorer final vision was associated with poorer baseline BCVA and diagnosis of central retinal vein occlusion after adjustment for age and sex (p<0.001 and 0.012, respectively). Significant elevation of IOP was noted at 3 months in the PSTA group, but ...


Bel Marra Health

Branch retinal vein occlusion (BRVO) recovery: Causes, symptoms, and treatment
Bel Marra Health
Branch retinal vein occlusion or BRVO is often referred to as an “eye stroke” and can impact a person's ability to see. The degree of vision loss varies in each sufferer. There are some cases where a person can recover from BRVO. Here we look at the ...

» Load more